<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03943251</url>
  </required_header>
  <id_info>
    <org_study_id>HEC113995PA•H2O-P-01/CRC-C19</org_study_id>
    <nct_id>NCT03943251</nct_id>
  </id_info>
  <brief_title>The Study of a Selective Serotonin Partial Agonist and Reuptake Inhibitors, HEC113995PA•H2O,in Healthy Subjects</brief_title>
  <official_title>Safety, Tolerability, and Pharmacokinetics Phase ⅠStudy of a Selective Serotonin Partial Agonist and Reuptake Inhibitors, HEC113995PA•H2O, Following Single Ascending Doses，Single-center, Randomized, Double-blind in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunshine Lake Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunshine Lake Pharma Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a safety, tolerability, and pharmacokinetics phase Ⅰstudy of a selective&#xD;
      Serotonin partial agonist and reuptake inhibitors, HEC113995PA•H2O,in healthy subjects.This&#xD;
      study is the healthy adult subjects single ascending-dose research.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There have set up seven dose group(2.5、5、10、20、40、60、80mg）.The first group(2.5mg)contains 8&#xD;
      health subjects(6 health subjects take experimental drugs,2 health subjects take the&#xD;
      placebo). Other groups contains 10 health subjects(8 health subjects take experimental&#xD;
      drugs,2 health subjects take the placebo).Within 30min before taking the medicine and after&#xD;
      0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 8h, 10h, 24h, 36h, 48h,72h to take blood samples&#xD;
      for pharmacokinetics(PK) detection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 4, 2019</start_date>
  <completion_date type="Actual">December 11, 2019</completion_date>
  <primary_completion_date type="Actual">December 11, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events of the single ascending-dose</measure>
    <time_frame>From the baseline to day4</time_frame>
    <description>To assess the safe and tolerability of the single ascending-dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration(Cmax)</measure>
    <time_frame>Prior to dosing（0.5h）and 0.5h,1h,1.5h,2h,2.5h,3h,4h,5h,6h,8h,10h,12h,24h,36h,48h,72h after dosing</time_frame>
    <description>Maximum Plasma Concentration(Cmax)of HEC113995PA•H2O in single ascending-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve(AUC)</measure>
    <time_frame>Prior to dosing（0.5h）and 0.5h,1h,1.5h,2h,2.5h,3h,4h,5h,6h,8h,10h,12h,24h,36h,48h,72h after dosing</time_frame>
    <description>Area Under the Curve(AUC) of HEC113995PA•H2O in single ascending-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Peak Time(Tmax)</measure>
    <time_frame>Prior to dosing（0.5h）and 0.5h,1h,1.5h,2h,2.5h,3h,4h,5h,6h,8h,10h,12h,24h,36h,48h,72h after dosing</time_frame>
    <description>Maximum Peak Time(Tmax) of HEC113995PA•H2O in single ascending-dose</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Mean Residence Time(MRT)</measure>
    <time_frame>Prior to dosing（0.5h）and 0.5h,1h,1.5h,2h,2.5h,3h,4h,5h,6h,8h,10h,12h,24h,36h,48h,72h after dosing</time_frame>
    <description>Mean Residence Time(MRT) of HEC113995PA•H2O in single ascending-dose</description>
  </other_outcome>
  <other_outcome>
    <measure>Terminal elimination half-life(T1/2)</measure>
    <time_frame>Prior to dosing（0.5h）and 0.5h,1h,1.5h,2h,2.5h,3h,4h,5h,6h,8h,10h,12h,24h,36h,48h,72h after dosing</time_frame>
    <description>Terminal elimination half-life(T1/2) of HEC113995PA•H2O in single ascending-dose</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>HEC113995PA•H2O tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Including 7 dose groups(2.5-、5、10-、20-、40-、60-、80mg).Each dose group was given only once.After an overnight stay of at least 10h on an empty stomach, 240mL of water was administered in the morning under the condition of an empty stomach. Water was forbidden for 1h before and 1h after administration, and fasting for 4h after administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Including 7 dose groups(2.5-、5、10-、20-、40-、60-、80mg).Each dose group was given only once.After an overnight stay of at least 10h on an empty stomach, 240mL of water was administered in the morning under the condition of an empty stomach. Water was forbidden for 1h before and 1h after administration, and fasting for 4h after administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HEC113995PA•H2O tablet</intervention_name>
    <description>2.5-、5-、10-、20-、40-、60-、80mg HEC113995PA•H2O tablet in day1.</description>
    <arm_group_label>HEC113995PA•H2O tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablet</intervention_name>
    <description>2.5-、5-、10-、20-、40-、60-、80mg Placebo tablet in day1.</description>
    <arm_group_label>placebo tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing to participate in the study, able to understand and sign the informed consent,&#xD;
             and able to complete the the study in accordance with the requirements of the study.&#xD;
&#xD;
          -  Female subjects who are not pregnant or lactating and male subjects whose female&#xD;
             partners are fertile shall voluntarily take effective contraceptive measures from the&#xD;
             date of signing the informed consent form to 3 months after the medication.&#xD;
&#xD;
          -  When signing the informed consent, 18 years old ≤the age≤45 years old, gender is not&#xD;
             limited.&#xD;
&#xD;
          -  Male body weight ≥50kg, female body weight ≤45kg, and body mass index (BMI) in the&#xD;
             range of 18-28 kg/m2 (including the critical value).&#xD;
&#xD;
          -  No clinical significance of vital signs, physical examination, laboratory examination,&#xD;
             chest X-ray (posterior and anterior) and electrocardiogram results.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The serum creatinine, ALT and AST levels ≥1.5 times of the normal upper limit in the&#xD;
             screening period.&#xD;
&#xD;
          -  The HbsAg, anti-HCV, HIV-antibody or syphilis antibody is positive in screening.&#xD;
&#xD;
          -  Patients with clinical significance of the following diseases, including but not&#xD;
             limited to gastrointestinal, kidney, liver, nerve, blood, endocrine, tumor, lung,&#xD;
             immune, mental or cardiovascular diseases, epilepsy, bipolar disorder/mania, high&#xD;
             intraocular pressure or acute angle-closure glaucoma disease history.&#xD;
&#xD;
          -  Those who are known to have allergy history or allergy constitution to the test&#xD;
             preparation and any of its components or related preparations.&#xD;
&#xD;
          -  Any prescription or over-the-counter medication taken within 14 days prior to starting&#xD;
             the study drug, or any drug that inhibits or induces the liver to metabolize the drug&#xD;
             within 28 days [e.g., inducer - the barbiturates, rifampicin, carbamazepine,&#xD;
             phenytoin, omeprazole, griseofulvin, ammonia methyl propyl ester, etc.; inhibitors -&#xD;
             large ring lactone class antibiotic (such as erythromycin, clarithromycin, etc.),&#xD;
             azole antifungal drugs (such as ketone health zun, itraconazole, etc.),&#xD;
             fluoroquinolone (e.g., ciprofloxacin, sand magnitude), calcium channel blockers (such&#xD;
             as verapamil, diltiazem, etc.), H1 receptor antagonist (e.g., astemizole, etc.), H2&#xD;
             receptor antagonist (e.g., cimetidine, etc.), SSRI antidepressants (such as&#xD;
             fluoxetine, fluvoxamine, etc.), benzodiazepines a tranquilizer, clopidogrel,&#xD;
             gemfibrozil, deferasirox, teriflunomide, telithromycin, trimethoprim, HMG-CoA&#xD;
             reductase inhibitors (such as lovastatin, simvastatin, etc.), nitroimidazoles, etc.&#xD;
&#xD;
          -  Those who ingested food or drink containing caffeine, xanthine, alcohol or grapefruit&#xD;
             within 48 hours before taking the study drug.&#xD;
&#xD;
          -  The urine drug abuse screening(morphine, tetrahydrocannabinolate, methamphetamine,&#xD;
             dimethylene dioxyamphetamine, ketamine, and cocaine) is positive.&#xD;
&#xD;
          -  Intemperant or regular drinkers within 3 months prior to the study, i.e., those who&#xD;
             consumed more than 21 units of alcohol per week (1 unit =360mL beer or 45mL spirit&#xD;
             with 40% alcohol or 150mL wine), or those who were positive on the alcohol breath&#xD;
             test.&#xD;
&#xD;
          -  A heavy smoker or smokers who smoke more than 10 cigarettes per day within 3 months&#xD;
             prior to administration or who fail to comply with the no smoking regulation during&#xD;
             the study.&#xD;
&#xD;
          -  Those who had a blood donation or blood loss of &gt;400mL within one month before taking&#xD;
             the study drug.&#xD;
&#xD;
          -  Those who plan to receive an organ transplant or have had one.&#xD;
&#xD;
          -  Those who have participated in clinical trials of other drugs within 3 months before&#xD;
             randomization.&#xD;
&#xD;
          -  Subjects considered by the investigator to have other factors unsuitable for&#xD;
             participation in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Shanghai xuhui district central hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 7, 2019</study_first_submitted>
  <study_first_submitted_qc>May 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2019</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

